Celltrion has shed further light on plans for its CT-P47 proposed biosimilar to Actemra/RoActemra (tocilizumab), revealing that it now has an approved global clinical trial design for the candidate as it prepares to push the product into Phase III.
Announcing plans to “speed up global Phase III clinical trials for patients in Europe, to expand the autoimmune disease portfolio,”...






